Qsymia for Weight Loss: Phentermine and Topiramate Benefits, Risks and Alternatives
Learn how Qsymia works, who may qualify, how much weight people may lose, important pregnancy and safety precautions, and how it compares with phentermine, Wegovy, Zepbound, Foundayo, and other treatments.
Qsymia is a prescription weight-management medication containing two active ingredients: phentermine and extended-release topiramate. The combination affects complementary appetite and satiety pathways and generally produces greater average weight loss than phentermine alone.
The FDA first approved Qsymia for adults in 2012. Its indication was expanded in 2022 to include certain adolescents aged 12 years and older with obesity. The first FDA-approved generic phentermine/topiramate extended-release product was approved in 2024.
Qsymia remains an effective oral treatment despite the arrival of newer GLP-1 and GIP/GLP-1 medications. It may be particularly useful for patients who prefer a pill, do not qualify for a GLP-1 treatment, cannot obtain insurance coverage for one, or need a more affordable alternative.
What is Qsymia?
Qsymia is a once-daily extended-release capsule used with reduced-calorie nutrition and increased physical activity for chronic weight management.
It contains:
- Phentermine: a sympathomimetic appetite suppressant that can reduce hunger and eating drive.
- Topiramate extended-release: a formulation of an antiseizure medication that can reduce appetite, increase fullness, and change the rewarding qualities of some foods.
Phentermine is a Schedule IV controlled substance. Topiramate is not a controlled substance, but the fixed-dose Qsymia product is controlled because it contains phentermine.
Qsymia is intended for chronic weight management. This distinguishes it from phentermine by itself, which is FDA-approved only for short-term use.
What is phentermine?
Phentermine is one of the longest-used prescription appetite suppressants in the United States. It stimulates the release of certain neurotransmitters, including norepinephrine, which can reduce hunger.
Common concerns include dry mouth, constipation, insomnia, nervousness, increased heart rate, and possible blood-pressure effects. It is not appropriate for every patient, particularly those with certain cardiovascular, thyroid, psychiatric, substance-use, or medication histories.
What is topiramate?
Topiramate was originally developed as an antiseizure medication and is also used for migraine prevention. Weight loss was observed as an effect of treatment, leading to its development in combination with phentermine for obesity.
Topiramate can cause tingling, taste changes, cognitive difficulties, metabolic acidosis, kidney stones, mood effects, and fetal harm. It should not be started, stopped, or changed without appropriate medical supervision.
How does phentermine/topiramate promote weight loss?
Appetite regulation involves many overlapping brain, gastrointestinal, hormonal, reward, and metabolic pathways. When only one pathway is targeted, compensatory signals may limit the response.
Primarily reduces hunger through sympathomimetic effects on appetite-regulating pathways.
May enhance fullness, reduce appetite, and alter cravings or food reward through several neurologic mechanisms.
Targets more than one pathway while using less phentermine and topiramate than might otherwise be required separately.
Qsymia does not melt fat or permanently change metabolism. It supports weight loss primarily by making a reduced-calorie eating plan easier to follow. Long-term nutrition, activity, sleep, behavioral support, and maintenance remain important.
Who may qualify for Qsymia?
Adults
Qsymia may be considered for adults with:
- A BMI of 30 kg/m² or higher; or
- A BMI of 27 kg/m² or higher with at least one weight-related medical condition.
Examples of weight-related conditions include:
- High blood pressure
- High cholesterol or triglycerides
- Type 2 diabetes or prediabetes
- Obstructive sleep apnea
- Fatty liver disease
- Osteoarthritis or mobility limitations
- Other clinically significant complications of excess weight
Adolescents
Qsymia is FDA-approved for chronic weight management in certain patients aged 12 years and older with obesity, generally defined using an age- and sex-standardized BMI at or above the 95th percentile.
Pediatric treatment requires specialized assessment, family involvement, nutrition and activity support, pregnancy precautions when applicable, and monitoring of growth. Qsymia may reduce height velocity in adolescents, so growth must be followed carefully.
It is not known to be safe and effective in children younger than 12 years.
How much weight can someone lose with Qsymia?
Results vary by dose, baseline weight, adherence, medical conditions, nutrition, activity, sleep, and individual response. In clinical trials lasting approximately one year, average weight reduction was generally:
- Approximately 7%–8% with the standard maintenance dose
- Approximately 9%–11% with the highest maintenance dose
- Substantially less with placebo and lifestyle support alone
For a person starting at 250 pounds:
- 5% weight loss is approximately 12.5 pounds
- 8% weight loss is approximately 20 pounds
- 10% weight loss is approximately 25 pounds
These examples are calculations, not promises. Some patients lose substantially more, while others lose little or stop because of adverse effects.
Qsymia dosing and response monitoring
Qsymia is taken once daily in the morning, with or without food. Evening administration is generally avoided because the phentermine component may cause insomnia.
The available fixed-dose strengths are:
- 3.75 mg phentermine/23 mg topiramate ER
- 7.5 mg phentermine/46 mg topiramate ER
- 11.25 mg phentermine/69 mg topiramate ER
- 15 mg phentermine/92 mg topiramate ER
Typical adult escalation framework
- Begin with 3.75 mg/23 mg once daily for 14 days.
- Increase to 7.5 mg/46 mg once daily.
- Evaluate the response after 12 weeks on 7.5 mg/46 mg.
- If at least 3% of starting weight has not been lost, treatment may be stopped or escalated.
- When escalating, 11.25 mg/69 mg is used for 14 days before increasing to 15 mg/92 mg.
- Evaluate again after 12 weeks on 15 mg/92 mg.
- If at least 5% of starting weight has not been lost, the medication should generally be discontinued gradually because meaningful long-term benefit is unlikely.
This is general label-based information, not a personal dosing plan. Kidney or liver impairment, adverse effects, other medications, age, and individual response can change the appropriate regimen.
What should be monitored?
Depending on the patient, monitoring may include:
- Body weight and waist circumference
- Blood pressure and heart rate
- Pregnancy testing when applicable
- Mood, anxiety, sleep, and suicidal thoughts
- Attention, memory, and word-finding difficulty
- Kidney function
- Serum bicarbonate, potassium, and other laboratory measures
- Eye symptoms
- Hydration and kidney-stone risk
- Height velocity in adolescents
- Medication effectiveness after the defined trial periods
Qsymia side effects
Common adverse effects
- Tingling or numbness, especially in the fingers or toes
- Dizziness
- Altered or metallic taste
- Insomnia
- Constipation
- Dry mouth
Important potential risks
| Concern | Why it matters |
|---|---|
| Fetal harm | Early pregnancy exposure is associated with an increased risk of oral clefts. |
| Increased heart rate | Heart rate should be monitored, particularly in patients with cardiovascular concerns. |
| Mood and sleep disorders | Depression, anxiety, irritability, insomnia, or suicidal thinking may occur. |
| Cognitive effects | Attention, memory, concentration, and word-finding problems are possible. |
| Acute glaucoma | Sudden eye pain or vision change requires immediate medical attention. |
| Metabolic acidosis | Topiramate can lower serum bicarbonate and disturb acid–base balance. |
| Kidney stones | Topiramate can increase kidney-stone risk; hydration may be important. |
| Low potassium | Risk may be greater with some diuretics and requires laboratory monitoring in selected patients. |
| Reduced sweating and overheating | This may be particularly important in hot weather and in adolescents. |
| Slowed growth | Height velocity should be monitored in adolescents. |
Contact the prescribing clinician promptly for persistent mood changes, severe cognitive effects, troublesome palpitations, significant adverse effects, or symptoms of a kidney stone.
Seek urgent medical attention for sudden eye pain or vision loss, severe allergic symptoms, suicidal intent, severe confusion, or another potentially life-threatening reaction.
Who should not take Qsymia?
Qsymia is contraindicated in people who:
- Are pregnant
- Have glaucoma
- Have hyperthyroidism
- Are taking a monoamine oxidase inhibitor or have taken one within the prohibited period
- Have a known hypersensitivity to its ingredients or sympathomimetic amines
Additional caution or a different treatment may be needed with cardiovascular disease, uncontrolled blood pressure, kidney stones, kidney or liver impairment, metabolic acidosis, depression, suicidal thoughts, cognitive concerns, seizure history, substance-use disorder, or interacting medications.
Pregnancy prevention and testing
Patients who can become pregnant should have a negative pregnancy test before treatment and repeat testing at intervals consistent with current prescribing requirements. Effective contraception is necessary throughout treatment.
If pregnancy occurs, Qsymia should be stopped and the prescribing clinician contacted immediately. Weight-loss medication is not used during pregnancy.
Qsymia compared with other weight-loss medications
The percentages below are approximate averages from separate trials. They are not guaranteed outcomes or direct head-to-head comparisons.
| Medication | How taken | Approximate average loss | Potential strengths | Important limitations |
|---|---|---|---|---|
| Qsymia | Daily capsule | About 7%–11% | Effective oral option; generic available; often less costly than branded GLP-1 therapy | Controlled substance, fetal harm, cognitive and mood effects |
| Phentermine alone | Usually daily | Often about 3%–7% over shorter periods | Low cost and rapid appetite suppression | FDA-approved only for short-term use; stimulant-related effects |
| Zepbound | Weekly injection | About 15%–21% | Among the greatest average losses; obesity-related OSA indication | GI effects, injection, contraindications, cost and coverage |
| Wegovy injection | Weekly injection | About 15% | Strong evidence; cardiovascular-risk-reduction indication for certain adults | GI effects, injection, cost, coverage and contraindications |
| Wegovy HD | Higher-dose weekly injection | About 18.8% in its supporting adult obesity trial | Greater average loss than standard Wegovy in the supporting trial | Not appropriate or tolerable for every patient |
| Wegovy tablets | Daily tablet | About 13.6% | No injection; semaglutide treatment | Specific food and water timing requirements |
| Foundayo | Daily tablet | About 7%–11% by dose in the primary analysis | Oral GLP-1 with no fasting or water restriction | GI effects and drug-interaction considerations |
| Contrave | Twice-daily tablets after escalation | About 5%–9% | May help selected patients with cravings or food reward | Cannot be used with opioids; seizure and blood-pressure concerns |
| Saxenda | Daily injection | About 5%–8% | Long clinical experience; pediatric indication for selected patients | Daily injection and less average loss than newer incretin therapies |
| Orlistat | With fat-containing meals | About 3%–5% | Non-stimulant; lower-dose OTC option | Gastrointestinal effects and nutrient-absorption considerations |
Qsymia versus Zepbound or Wegovy
Zepbound and Wegovy generally produce greater average weight loss than Qsymia. They may also offer specific benefits for selected patients with cardiovascular disease, type 2 diabetes, or obstructive sleep apnea.
Qsymia may still be preferred when:
- The patient wants an oral medication
- GLP-1 treatment is not covered or affordable
- A GLP-1 medicine caused intolerable gastrointestinal effects
- The patient has no contraindication to phentermine or topiramate
- Qsymia previously worked well
- A stimulant-containing approach is considered appropriate
Learn more about semaglutide, tirzepatide, and Foundayo.
Qsymia versus separately prescribed generic components
Some clinicians prescribe generic phentermine and generic immediate-release topiramate separately. This may cost less, but it is not identical to Qsymia or an FDA-approved generic equivalent.
Important differences may include:
- Immediate-release versus extended-release topiramate
- Different dose ratios
- Different absorption and blood-level patterns
- Separate pills rather than one fixed-dose capsule
- Off-label use of the separate combination
- Different evidence, labeling, pharmacy handling, and insurance treatment
An FDA-approved generic equivalent to Qsymia is more directly comparable to the branded extended-release product than two separately prescribed generic tablets.
Qsymia cost, insurance, and generic availability
The old fixed monthly price estimates for Qsymia are no longer reliable. Actual cost varies according to:
- Brand-name versus FDA-approved generic medication
- Prescribed strength
- Insurance formulary and deductible
- Prior-authorization requirements
- Retail, mail-order, or specialty-pharmacy arrangements
- Manufacturer or pharmacy savings programs
- Whether the clinician uses separate generic components off-label
Patients should compare the total cost of the medication, medical follow-up, laboratory monitoring, and any required pregnancy testing—not simply the advertised price of a prescription.
Does Qsymia require a very-low-calorie diet?
No. Qsymia should be combined with reduced-calorie nutrition and increased physical activity, but an 800-calorie diet is not required or appropriate for everyone.
A very-low-calorie diet is an intensive medical intervention that may be used for carefully selected patients under close supervision. It requires attention to:
- Adequate protein and essential nutrients
- Hydration and electrolyte balance
- Medication adjustments
- Gallstone risk
- Loss of muscle and lean body mass
- Transition to sustainable food
- Long-term maintenance
Many patients do better with a moderate individualized calorie deficit, adequate protein, resistance exercise, and a plan they can maintain over time.
What happens after weight loss?
Obesity is a chronic disease. Appetite can rise and energy expenditure can decline after weight loss, increasing the risk of recurrence. Qsymia therefore should not be viewed only as a short-term “diet pill.”
A long-term strategy may include:
- Continuing an effective maintenance treatment when appropriate
- Adjusting medication according to benefit and adverse effects
- Switching to another treatment when response is inadequate
- Preserving muscle through protein and resistance exercise
- Treating sleep apnea and inadequate sleep
- Monitoring weight trends before substantial regain occurs
- Addressing emotional eating, stress, and medication-related weight gain
Explore W8MD weight-loss maintenance strategies.
How W8MD can help with Qsymia and other weight-loss options
W8MD Weight Loss, Sleep & MedSpa has more than 20 years of experience with physician-supervised medical weight management. W8MD does not assume that one medication is best for every patient.
Depending on your medical needs and eligibility, W8MD may help with:
- Evaluation of obesity, overweight, insulin resistance, prediabetes, and metabolic syndrome
- Assessment of whether Qsymia, phentermine, or another medication is appropriate
- Comparison with Wegovy, Wegovy tablets, Wegovy HD, Zepbound, Foundayo, Saxenda, Contrave, and orlistat
- Review of cardiovascular, psychiatric, kidney, eye, pregnancy, and medication risks
- Pregnancy-safety counseling and testing when required
- Blood-pressure, heart-rate, weight, and laboratory monitoring
- Individualized nutrition and physical-activity planning
- Body-composition monitoring
- Sleep-apnea screening and home sleep testing when indicated
- Insurance and prior-authorization assistance when coverage is available
- Affordable generic options when clinically appropriate
- Long-term weight-maintenance planning
Learn more about W8MD medical weight loss, prescription weight-loss medications, and sleep-apnea screening.
Schedule an individualized consultation to compare Qsymia with phentermine, GLP-1 medications, oral options, and other treatments based on your health, goals, coverage, and budget.
Request an appointment Brooklyn: 718-946-5500 Philadelphia: 215-676-2334Frequently asked questions
Is Qsymia approved for long-term weight management?
Yes. Unlike phentermine alone, Qsymia is FDA-approved for chronic weight management when used with reduced-calorie nutrition and increased physical activity.
Is generic Qsymia available?
Yes. The FDA approved the first generic phentermine/topiramate extended-release capsules in 2024. Availability, coverage, and pharmacy pricing may vary.
Is taking generic phentermine and topiramate separately the same as Qsymia?
Not necessarily. Qsymia uses a specific fixed-dose combination with extended-release topiramate. Separately prescribed immediate-release generic medicines can differ in dosing, absorption, evidence, and FDA-approved status.
Is Qsymia stronger than phentermine?
Qsymia generally produces greater average weight loss because it combines phentermine with topiramate extended-release. It also has more complex safety, pregnancy, cognitive, and laboratory considerations.
Is Qsymia better than Wegovy or Zepbound?
Wegovy and Zepbound generally produce greater average weight loss. Qsymia may be preferable when an oral medication is desired, GLP-1 treatment is not tolerated or covered, or cost is a major concern. Medical history ultimately determines suitability.
Can Qsymia be used with a GLP-1 medication?
Combination treatment is not automatically appropriate and may not have the same evidence as individually approved regimens. A qualified clinician must assess cardiovascular effects, adverse reactions, medication interactions, and whether the potential benefit justifies the added risk.
Can Qsymia be used during pregnancy?
No. Qsymia is contraindicated during pregnancy because topiramate exposure can cause fetal harm. Appropriate pregnancy testing and contraception are required for patients who can become pregnant.
Can Qsymia be stopped suddenly?
The highest dose should not be stopped abruptly because sudden topiramate withdrawal can precipitate seizures. Discontinuation and tapering should be supervised by the prescriber.
What if Qsymia is not working?
The prescribing information uses defined response checkpoints. If a patient has not lost at least 3% after 12 weeks on 7.5 mg/46 mg, treatment may be stopped or escalated. If at least 5% is not lost after 12 weeks on 15 mg/92 mg, gradual discontinuation is generally recommended.
References and further information
- FDA: Qsymia Approved for Chronic Weight Management in Patients Aged 12 and Older
- FDA Prescribing Information: Qsymia
- FDA: First Generic Phentermine/Topiramate Extended-Release Approval
- NIDDK: Prescription Medications to Treat Overweight and Obesity
- WikiMD: Phentermine/Topiramate
- WikiMD: Phentermine
- WikiMD: Topiramate
Comments
Post a Comment